Menger et al. knocked out the PD-1 gene in melanoma-reactive CTLs and in fibrosarcoma-reactive polyclonal T cells, using the TALEN technology and noticed that modified T cells had better persistence at the cancer site and were able to control the tumor progression more efficiently than non-modified T cells (323). This evidence concerns the gene PDCD1 and neoplasm.